News and Conferences

Page 7 of 16

  1. NeuPSIG 2023

    International Congress on Neuropathic Pain; NeuPSIG, takes place 7-9 September in Lisbon, Portugal. This is the leading meeting for the latest research and developments in understanding the mechanisms, assessment, prevention and treatment of neuropathic pain.

  2. International League Against Epilepsy

    35th International Epilepsy Congress is taking place 2-6 September in Dublin, Ireland, promising a programme representing the best in global epileptology, Transpharmation looks forward to attending the sessions, meeting clients old and new.

  3. The 2023 Animal Health Summit

    The 2023 Animal Health Summit takes place August 28-29, in Kansas City, Missouri.

  4. Best Poster Winner!

    Transpharmation Scientist Malgorzata Potoczna's poster; "Evaluation of Anxiolytic Potential of Amitriptyline, Fluoxetine, and TP003 in Zebrafish Larvae Using the Light-Dark Challenge Assay" was selected as best PTZ Poster Presentation, at the recent 12th European Zebrafish Conference in Poland.

  5. Alzheimer's Association International Conference

    Alzeimer’s Association International Conference takes place 16-20 July 2023 in Amsterdam, Netherlands. With a reputation as the largest and most influential international conference on dementia science, Transpharmation looks forward to attending.

  6. Transpharmation Collaborates With Artelo Biosciences To Support Development Of Neuropathic Pain Treatment

    Transpharmation is delighted to have worked with Artelo Biosciences, Inc. to support development of the FABP5 inhibitor ART26.12 as a neuropathic pain treatment.

  7. 12th European Zebrafish Meeting

    Transpharmation will present a poster titled "Evaluation of Anxiolytic Potential of Amitriptyline, Fluoxetine, and TP003 in Zebrafish Larvae Using the Light-Dark Challenge Assay." Come along to Transpharmation’s booth to meet us.

  8. Transpharmation and Veterinary Health Research Centers Partnership

    Companies announce today at a strategic co-marketing partnership enabling the transition of preclinical research into clinical trials in animals.

  9. Published!

    Published! We're feeling proud of Sandor Kantor and his colleagues at Transpharmation as one of their recent studies about the sleep and EEG effects of ketamine in a rat model of treatment-resistant depression has been accepted for publication in Behavioural Brain Research, published by Elsevier.

  10. The Neuro4D Conference

    The Neuro4D Conference 15-16 May in Mainz, Germany is an international conference that unites drug discovery companies, service and technology providers and academic innovators who specialise in proteopathic neurodegenerative diseases. Transpharmation is pleased to be one of the event’s key sponsors.

Page 7 of 16

Want to see our latest study results?

Sign up for our newsletter.

Emails with our latest study results and news, from time to time. Unsubscribe anytime. See our Privacy Policy.

Newsletters

  • What's Next in CNS Drug Discovery? Five Studies Worth Exploring
  • Advancing Science Through In Vivo Refinement and Innovation - Examples from Abuse Liability and Impulsivity Screening
  • Building Confidence in Decision Making
  • Welcome to Reading, UK
  • The Next Leap in Translational Neuroscience
  • Expanding Scientific Possibility
  • 2025 Was A Year of Momentum: Science, People and Partners
  • 2025 Was A Year of Momentum: Science, People and Partners
  • Seven Posters, One Goal: Driving Neuroscience Forward
  • Advancing Preclinical Science for Next-Gen Therapies
  • New Capabilities Coming Online
  • Discover What's New at Transpharmation
  • Unlock the Microbiome: Transform Health with Transpharmation's Advanced Studies
  • Experimental Autoimmune Encephalomyelitis (EAE): Maximising The Therapeutic Efficacy of Fingolimod
  • Cross-Species Epilepsy Research: Revealing the Potential of the Zebrafish Model
  • Monoamine depletion to induce chronic allodynia and behavioural changes: a model of fibromyalgia
  • Take your R&D pipeline into the AI era with Moseq (Motion Sequencing), our new behavioural machine-learning assay!
  • Canine Microbiome
  • Oral Health: Not just for Humans
  • Novel Object Recognition: A Reliable Assay for Addressing Cognitive Impairments in Schizophrenia
  • Pre-pulse Inhibition: A Promising Screening Tool for Novel Compounds
  • Natural and induced models of osteoarthritis in Beagle dogs
  • Utilizing Rapid Screening Tests to Assess the Antidepressant Potential of Psychedelic Analogues
  • Long-term antidepressant effect of ketamine and psilocybin in the Chronic Social Defeat stress model
  • Diabetes and Metabolic Syndrome
  • Transpharmation's Animal Health Services
  • Longevity Research Goes to the Dogs
  • Transpharmation's Cutting-Edge Antiepileptic Drug Screening: A Global Solution for Advancing Epilepsy Research
  • PTZ-treated Zebrafish provide a high throughput platform for screening novel anti-epileptic drugs
  • Beyond Seizures: Epilepsy Comorbidities Explored in Mouse Kindling Studies
  • Novelty-suppressed feeding and novelty-induced hypophagia: exploring sex differences and response to diazepam in C57BL/6J mice.
  • Development & validation of intrathecal dosing in rats and mice
  • Transpharmation's Mouse-EEG capability reveals cross-species effects of novel antidepressants ketamine and psilocybin
  • Oral Health: Not just for Humans...
  • Accelerate Your Diabetes Drug Development with Transpharmation's Dog Diabetes Models
  • Introducing our new data analysis service for tremor-plate signals!
  • Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
  • New validated pre-clinical model to assess treatments for post-surgical pain
  • Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
  • New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
  • Do Your Compounds Exhibit Anti-Inflammatory Compounds
  • Profile your anti-inflammatory compounds in primary human immune cells
  • New EEG services from Transpharmation. Read on for results...
  • Accelerate your Drug Discovery Research. Proven results, fast and cost effective
  • Urgent Treatments Needed for Parkinson's Disease
  • Poor bioavailability, is the liver or intestine to blame?
  • Laser Doppler; new validated protocols revealed.
  • Epilepsy models leading the way. Read on for results.
  • Profiling anti-inflammatory drugs; from rodent to human
  • The Mismatch Negativity Challenge
  • Accelerate your drug discovery research. Proven science based results cost-effectively.
  • Anxiety. Three preclinical tests; data revealed...
  • Seven new posters, presented at SfN, now available to view.
  • Name change announcement! News from the CEO.
  • Chronic fatigue: different etiologies influence translational models
  • Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
  • Translational value increased with non-evoked pain measures.
  • Rapid access to PK non-rodent studies. Leading expertise.
  • Essential tremor research
  • Can a psychedelic experience be modelled in rats?
  • Gender Differences in Pain. New research revealed!
  • New data on the effect of single dose psilocybin!
  • From ketamine to psychedelics, join our webinar starting tomorrow!
  • Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
  • Accreditation awarded with flying colours
  • Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
  • Take a look! New posters, nine therapeutic areas available to view now.
  • Nine new compelling studies to be revealed at SfN21!
  • Can changes in EEG improve neuropathic pain treatments?
  • 40Hz ASSR: sounds that change our thoughts about schizophrenia
  • Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
  • Translational endpoints for preclinical pain - improving your chances.
  • Transpharmation aims for global standard. Let's talk about lab sustainability.
  • Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
  • Psilocybin: the power of mental reorganisation
  • Expansion to world class premises
  • Multiple therapeutic indications
  • Focus on pain
  • Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
  • Announcing Transpharmation Poland!